Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MASP2 | O00187 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 8/20 | 0.47 |
| ▸ | ACE | P12821 | 5/20 | 0.47 |
| ▸ | CPA1 | P15085 | 5/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29695560 | 0.99 | CTSC (0.58) | CTSCLMNATDP1MASP2REN | |
| SCHEMBL30689140 | 0.91 | CTSC (0.50) | CTSCMMEACECPA1ACE2 | |
| SCHEMBL29702042 | 0.90 | CTSC (0.63) | CTSCLMNATDP1RENMME | |
| SCHEMBL30546877 | 0.90 | CTSC (0.63) | CTSCLMNATDP1RENMME | |
| SCHEMBL29701979 | 0.90 | CTSC (0.63) | CTSCLMNATDP1RENMME | |
| SCHEMBL31026629 | 0.90 | CTSC (0.68) | CTSCLMNATDP1MMEACE | |
| SCHEMBL28122660 | 0.90 | CTSC (0.68) | CTSCLMNATDP1MMEACE | |
| SCHEMBL601567 | 0.90 | CTSC (0.68) | CTSCLMNATDP1MMEACE | |
| SCHEMBL21808154 | 0.90 | CTSC (0.68) | CTSCLMNATDP1MMEACE | |
| SCHEMBL28122659 | 0.90 | CTSC (0.68) | CTSCLMNATDP1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731002-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2026-04-29 | — | — | EP | claimed |
| WO-2025137591-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS | Tenfold Technologies, LLC (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2024263793-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2024-12-26 | — | — | WO | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4731002-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025137591-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS | Tenfold Technologies, LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2024263793-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-117210441-B | Low-temperature salt-tolerant beta-glucosidase and application thereof in conversion of ginsenoside Rb1 | 云南师范大学 | 2024-09-20 | — | — | CN | disclosed |
| CN-117210441-A | Low-temperature salt-tolerant beta-glucosidase and application thereof in conversion of ginsenoside Rb1 | 云南师范大学 | 2023-12-12 | — | — | CN | disclosed |
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | CTSC 131/4885LMNA 1538/4885TDP1 927/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | CTSC 37/4885LMNA 3184/4885TDP1 1709/4885 |
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SERPINC1, PLAT, F2 | CTSC 873/4885LMNA 999/4885TDP1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.